And then there were 8: Fre­se­nius nabs the lat­est Hu­mi­ra biosim­i­lar ap­proval

An­tic­i­pa­tion is build­ing as the US pre­pares for an on­slaught of biosim­i­lars com­pet­ing with Ab­b­Vie’s megablock­buster Hu­mi­ra in the com­ing months.

Fre­se­nius Kabi said this morn­ing that the FDA ap­proved its cit­rate-free biosim­i­lar to Hu­mi­ra (adal­i­mum­ab), known as Ida­cio. This is the eighth FDA ap­proval for an adal­i­mum­ab biosim­i­lar (first ap­proved in 2016), but none will launch un­til next year. Fre­se­nius pre­vi­ous­ly set­tled with Ab­b­Vie and plans to launch Ida­cio in Ju­ly 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER